About Protein RUFY3
Protein RUFY3 (RUFY3) is a protein
from Homo sapiens identified by UniProt accession
Q7L099, 469 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Protein RUFY3 |
| UniProt accession | Q7L099 |
| Gene | RUFY3 |
| Organism | Homo sapiens |
| Length | 469 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- diabetes mellitus · score 0.19
- type 2 diabetes mellitus · score 0.12
- serum metabolite measurement · score 0.09
- mean corpuscular volume · score 0.08
- subarachnoid hemorrhage · score 0.07
- Red cell distribution width · score 0.07
- mean corpuscular hemoglobin concentration · score 0.07
- MALT lymphoma · score 0.07
- triglyceride measurement · score 0.06
- Meckel's diverticulum · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7L099-F1 | alphafold | PREDICTED | 81.77 | — |
Amino-acid sequence (469 residues)
MSALTPPTDM PTPTTDKITQ AAMETIYLCK FRVSMDGEWL CLRELDDISL TPDPEPTHED PNYLMANERM NLMNMAKLSI KGLIESALNL GRTLDSDYAP LQQFFVVMEH CLKHGLKAKK TFLGQNKSFW GPLELVEKLV PEAAEITASV KDLPGLKTPV GRGRAWLRLA LMQKKLSEYM KALINKKELL SEFYEPNALM MEEEGAIIAG LLVGLNVIDA NFCMKGEDLD SQVGVIDFSM YLKDGNSSKG TEGDGQITAI LDQKNYVEEL NRHLNATVNN LQAKVDALEK SNTKLTEELA VANNRIITLQ EEMERVKEES SYILESNRKG PKQDRTAEGQ ALSEARKHLK EETQLRLDVE KELEMQISMR QEMELAMKML EKDVCEKQDA LVSLRQQLDD LRALKHELAF KLQSSDLGVK QKSELNSRLE EKTNQMAATI KQLEQSEKDL VKQAKTLNSA ANKLIPKHH
Explore Protein RUFY3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets